Impact on Survival of Heart and Heart-Lung Transplantation in Patients With Cyanotic and Noncyanotic Congenital Heart Diseases

被引：0
作者：
Donoso-Trenado, Victor [1 ,2 ]
Lopez-Vilella, Raquel [1 ,2 ]
Rueda-Soriano, Joaquin [2 ,3 ]
Buendia-Fuentes, Francisco [2 ,3 ]
Martinez-Dolz, Luis [2 ,4 ]
Almenar-Bonet, Luis [1 ,2 ,4 ,5 ]
机构：
[1] Hosp Univ & Politecn La Fe, Heart Failure & Transplantat Unit, Ave Fernando Abril Martorell 106, Valencia, Spain
[2] Hosp Univ & Politecn La Fe, Dept Cardiol, Valencia, Spain
[3] Hosp Univ & Politecn La Fe, Adult Congenital Heart Dis Unit, Valencia, Spain
[4] Ctr Invest Biomed Red Enfermedades Cardiovasc CIBE, Madrid, Spain
[5] Univ Valencia, Dept Med, Valencia 46026, Spain
来源：
TRANSPLANTATION PROCEEDINGS | 2025年 / 57卷 / 01期
关键词：
MANAGEMENT; OUTCOMES;
D O I：
10.1016/j.transproceed.2024.12.005
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background. A high percentage of patients with congenital heart diseases (CHD) reach adulthood and, over time, require heart transplantation (HTx) or combined heart-lung transplantation (HLTx). Among CHD, there are subgroups associated with a higher risk. Methods. Retrospective analysis of HTx and HLTx in CHD patients. They are subdivided based on the etiology of cyanotic or noncyanotic CHD. Baseline characteristics and mortality are comparatively analyzed. No comparative analysis is performed between HTx and HLTx. Results. A total of 1015 HTx were performed, 933 (91,9%) were first-time HTx, and 42 (4.1%) were HLTx. Of the HTx, 18 (1.8%) were in CHD patients. In the HLTx group, 18 (42.8%) had CHD. In the HTx group, cyanotic patients had fewer surgical interventions (57% vs. 18%), compared to noncyanotic patients, where corrective surgeries were more common. Cyanotic patients had a higher mortality rate (57.1% vs. 18.2%), and their median survival was slightly lower (15.9 vs. 16.7 years). In the HLTx group, ninety percent of cyanotic patients had no previous surgeries, compared to 25% in the other group. The mortality rate was higher in cyanotic patients (60% vs. 37.5%), and their median survival was lower (1.7 vs. 9.5 years). Mortality occurred mainly in the first 30 days and was higher in cyanotic patients. Conclusions. In CHD patients following HTx or HLTx, cyanotic conditions are associated with lower survival, with higher mortality occurring during the first 30 days.
引用
收藏
页码：86 / 89
页数：4
相关论文
共 12 条
  • [1] Baumgartner H., De Backer J., Babu-Narayan S.V., Budts W., Chessa M., Diller G.P., Et al., 2020 ESC Guidelines for the management of adult congenital heart disease: the Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Adult Congenital Heart Disease (ISACHD), Eur Heart J, 42, 6, pp. 563-645, (2021)
  • [2] Moons P., Hilderson D., Van Deyk K., Implementation of transition programs can prevent another lost generation of patients with congenital heart disease, Eur J Cardiovasc Nurs, 7, pp. 259-263, (2008)
  • [3] Deanfield J., Thaulow E., Warnes C., Webb G., Kolbel F., Hoffman A., Et al., Management of grown up congenital heart disease, Eur Heart J, 24, pp. 1035-1084, (2003)
  • [4] Khairy P., Ionescu-Ittu R., Mackie A.S., Abrahamowicz M., Pilote L., Marelli A.J., Changing mortality in congenital heart disease, J Am Coll Cardiol, 56, pp. 1149-1157, (2010)
  • [5] Diller G.P., Kempny A., Alonso-Gonzalez R., Swan L., Uebing A., Li W., Et al., Survival prospects and circumstances of death in contemporary adult congenital heart disease patients under follow-up at a large tertiary centre, Circulation, 132, pp. 2118-2125, (2015)
  • [6] Tutarel O., Kempny A., Alonso-Gonzalez R., Jabbour R., Li W., Uebing A., Et al., Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality, Eur Heart J, 35, pp. 725-732, (2014)
  • [7] Davies R.R., Russo M.J., Yang J., Quaegebeur J.M., Mosca R.S., Chen J.M., Listing and transplanting adults with congenital heart disease, Circulation, 123, pp. 759-767, (2011)
  • [8] Becher P.M., Schrage B., Weimann J., Smits J., Magnussen C., Reichenspurner H., Et al., Clinical characteristics and outcomes of patients with adult congenital heart disease listed for heart and heart-lung transplantation in the Eurotransplant region, J Heart Lung Transplant, 39, 11, pp. 1238-1249, (2020)
  • [9] Doumouras B.S., Alba A.C., Foroutan F., Burchill L.J., Dipchand A.I., Ross H.J., Outcomes in adult congenital heart disease patients undergoing heart transplantation: a systematic review and meta-analysis, J Heart Lung Transplant, 35, 11, pp. 1337-1347, (2016)
  • [10] Goerler H., Simon A., Gohrbandt B., Hagl C., Oppelt P., Weidemann J., Et al., Heart—lung and lung transplantation in grown-up congenital heart disease: long-term single centre experience, Eur J Cardiothorac Surg, 32, pp. 926-931, (2007)
12